文献速递淋巴瘤

TP53和CDKN2A改变定义结内T滤泡辅助细胞淋巴瘤患者的不良预后亚组

TP53 and CDKN2A alterations define a poor prognostic subgroup in patients with nodal T follicular helper cell lymphoma.
PubMed 文献 · Leukemia · 2025-05-02

分析173例结内T滤泡辅助细胞淋巴瘤(nTFHL)病例,鉴定出36个驱动基因,按主要驱动改变分为四个分子亚组,其中AC53亚组(TP53和/或CDKN2A改变及非整倍体)生存最差,NSD亚组预后最好;多变量分析显示AC53、驱动改变存在及国际预后指数高危与更差生存独立相关,并开发了mTFHL-PI预后指数将患者分为三个风险类别。

要点

  • nTFHL按主要驱动改变可分为TR-I(+)、TR-I(-)、AC53和NSD四个分子亚组。
  • AC53亚组(TP53和/或CDKN2A改变及非整倍体)生存最差,NSD亚组预后最好。
  • mTFHL-PI将患者分为三个风险类别,中位OS分别为181、67和20个月。

核心结论

  • TP53和/或CDKN2A改变及驱动改变的存在是nTFHL新的预后因素,分子分类具有临床相关性。

研究设计与样本

  • 分析173例nTFHL病例,鉴定驱动基因并按主要驱动改变进行分子分型。

主要发现

  • 鉴定出36个驱动基因,包括4个新基因(TET3、HLA-C、NRAS和KLF2)。
  • AC53亚组生存最差,NSD亚组(尤其缺乏驱动改变者)预后最好。
  • 无TP53和/或CDKN2A改变时,nTFHL预后优于非特指型外周T细胞淋巴瘤。
  • 多变量分析显示AC53、驱动改变存在及国际预后指数高危与更差生存独立相关。
  • mTFHL-PI将患者分为三个风险类别,中位OS分别为181、67和20个月。

关键数值与推荐

  • TR-I(+)和TR-I(-)分别以伴和不伴IDH2突变的TET2和/或RHOA突变为特征。
  • AC53以TP53和/或CDKN2A改变及非整倍体为特征。
  • NSD为无亚组定义性改变(即无上述任何改变)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Nodal T follicular helper cell lymphoma (nTFHL) exhibits unique immunophenotypes and somatic alterations, while the prognostic value of these alterations remains unclear. By analyzing 173 nTFHL cases, we identified 36 driver genes, including 4 novel ones (TET3, HLA-C, NRAS, and KLF2). Then, we classified nTFHL cases into four molecular subgroups by major driver alterations. TR-I (+) and TR-I (-) were characterized by TET2 and/or RHOA mutations with and without IDH2 mutations; AC53 by TP53 and/or CDKN2A alterations and aneuploidy; and NSD with no subgroup-defining alterations (namely without any of the above alterations). AC53 exhibited the worst survival, while NSD, particularly those lacking driver alterations, showed the best prognosis. nTFHL had a better prognosis than peripheral T-cell lymphoma, not otherwise specified, when TP53 and/or CDKN2A alterations were absent. Multivariable analyses showed that AC53, the presence of driver alterations, and international prognostic index high-risk were independently associated with worse survival. Finally, we developed a simple prognostic index (mTFHL-PI), which classified patients into three risk categories with a median OS of 181, 67, and 20 months, respectively. Our study identifies novel prognostic factors, namely TP53 and/or CDKN2A alterations and the presence of driver alterations, demonstrating the clinical relevance of molecular classification in nTFHL.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Ito Y, Shimono J, Kawamoto K, et al. TP53 and CDKN2A alterations define a poor prognostic subgroup in patients with nodal T follicular helper cell lymphoma. Leukemia. 2025. PMID: 40316697. doi:10.1038/s41375-025-02631-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。